Ligand Pharmaceuticals
LGND
174 hedge funds and large institutions have $1.04B invested in Ligand Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 73 increasing their positions, 58 reducing their positions, and 37 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 58
9.38% more ownership
Funds ownership: 100.35% → 109.73% (+9.4%)
9% less funds holding
Funds holding: 192 → 174 (-18)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
20% less capital invested
Capital invested by funds: $1.3B → $1.04B (-$259M)
40% less call options, than puts
Call options by funds: $5.04M | Put options by funds: $8.41M
49% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
+$26.4M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$22.5M |
| 3 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$19.6M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$14.6M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$41.7M |
| 2 |
CCI
Columbus Circle Investors
|
-$16.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.2M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.51M |
| 5 |
TA
Teachers Advisors
New York
|
-$8.75M |
LGND Hedge Fund Activity: Q3 2014 in Review
174 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2014, worth a combined $1.04B — down 20% from $1.3B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of LGND and 19 opened new positions — a net loss of 18 holders — while 58 trimmed existing stakes and 73 added.
The largest buyer was Gotham Asset Management, adding an estimated $26.4M. The largest seller was BVF Inc, cutting an estimated $41.7M.
- 174 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2014, down from 192 in Q2 2014.
- Funds reported $1.04B of Ligand Pharmaceuticals stock for Q3 2014, down 20% quarter-over-quarter.
- 19 funds opened new Ligand Pharmaceuticals positions in Q3 2014 and 37 closed out, a net change of -18 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2014 was Gotham Asset Management, an estimated $26.4M added.
- The largest Ligand Pharmaceuticals seller in Q3 2014 was BVF Inc, an estimated $41.7M sold.
Based on aggregated 13F filings for Q3 2014.